TY - JOUR
T1 - Evaluation of a novel continuous real time 13C urea breath analyser for Helicobacter pylori
AU - Shirin, H.
AU - Kenet, G.
AU - Shevah, O.
AU - Wardi, Y.
AU - Birkenfeld, S.
AU - Shahmurov, M.
AU - Bruck, R.
AU - Niv, Y.
AU - Moss, S. F.
AU - Avni, Y.
PY - 2001
Y1 - 2001
N2 - Aim: To evaluate the sensitivity and specificity of a new 13C urea breath test. Oridion BreathID, for the diagnosis of Helicobacter pylori. Methods: A total of 97 consecutive symptomatic patients referred for upper endoscopy were included in the 'pre-therapy' part of the study. After endoscopy the patients were analysed for H. pylori by Oridion BreathID. BreathID continuously sampled the subject's breath for 20 min. and displayed the results on the BreathID screen in real time. Results of the BreathID were compared with the 'gold standard' (rapid urease test and histology). We also prospectively tested the validity of BreathID in comparison to isotope ratio mass spectrometry, in 40 patients referred to monitor the efficacy of H. pylori eradication treatment. Results: Complete agreement was observed between the 'gold standard' and the Breath ID test in 96.9% (94 out of 97) of the patients. The sensitivity and specificity of BreathID were 97.8% and 96.1%. respectively. The correlation between BreathID and isotope ratio mass spectrometry breath test was 100%. Conclusions: The Oridion BreathID has comparable sensitivity and specificity to the claims of the currently available urea breath tests. Furthermore, BreathID has the potential advantages of ease of use with minimal medical staff requirement, and real time rapid results (20 min maximum) which may make the BreathID preferable to other urea breath test assays.
AB - Aim: To evaluate the sensitivity and specificity of a new 13C urea breath test. Oridion BreathID, for the diagnosis of Helicobacter pylori. Methods: A total of 97 consecutive symptomatic patients referred for upper endoscopy were included in the 'pre-therapy' part of the study. After endoscopy the patients were analysed for H. pylori by Oridion BreathID. BreathID continuously sampled the subject's breath for 20 min. and displayed the results on the BreathID screen in real time. Results of the BreathID were compared with the 'gold standard' (rapid urease test and histology). We also prospectively tested the validity of BreathID in comparison to isotope ratio mass spectrometry, in 40 patients referred to monitor the efficacy of H. pylori eradication treatment. Results: Complete agreement was observed between the 'gold standard' and the Breath ID test in 96.9% (94 out of 97) of the patients. The sensitivity and specificity of BreathID were 97.8% and 96.1%. respectively. The correlation between BreathID and isotope ratio mass spectrometry breath test was 100%. Conclusions: The Oridion BreathID has comparable sensitivity and specificity to the claims of the currently available urea breath tests. Furthermore, BreathID has the potential advantages of ease of use with minimal medical staff requirement, and real time rapid results (20 min maximum) which may make the BreathID preferable to other urea breath test assays.
UR - http://www.scopus.com/inward/record.url?scp=0035119107&partnerID=8YFLogxK
U2 - 10.1046/j.1365-2036.2001.00926.x
DO - 10.1046/j.1365-2036.2001.00926.x
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 11207514
AN - SCOPUS:0035119107
SN - 0269-2813
VL - 15
SP - 389
EP - 394
JO - Alimentary Pharmacology and Therapeutics
JF - Alimentary Pharmacology and Therapeutics
IS - 3
ER -